[go: up one dir, main page]

LT2900269T - Regorafenibo ir acetilsalicilo rūgšties derinys kolorektalinio vėžio gydymui - Google Patents

Regorafenibo ir acetilsalicilo rūgšties derinys kolorektalinio vėžio gydymui

Info

Publication number
LT2900269T
LT2900269T LTEP13770659.4T LT13770659T LT2900269T LT 2900269 T LT2900269 T LT 2900269T LT 13770659 T LT13770659 T LT 13770659T LT 2900269 T LT2900269 T LT 2900269T
Authority
LT
Lithuania
Prior art keywords
regorafenib
combination
colorectal cancer
acetylsalicylic acid
treating colorectal
Prior art date
Application number
LTEP13770659.4T
Other languages
English (en)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2900269(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Ag filed Critical Bayer Pharma Aktiengesellschaft
Publication of LT2900269T publication Critical patent/LT2900269T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP13770659.4T 2012-09-25 2013-09-23 Regorafenibo ir acetilsalicilo rūgšties derinys kolorektalinio vėžio gydymui LT2900269T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (1)

Publication Number Publication Date
LT2900269T true LT2900269T (lt) 2018-11-12

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13770659.4T LT2900269T (lt) 2012-09-25 2013-09-23 Regorafenibo ir acetilsalicilo rūgšties derinys kolorektalinio vėžio gydymui

Country Status (29)

Country Link
US (1) US10898500B2 (lt)
EP (1) EP2900269B1 (lt)
JP (1) JP6294888B2 (lt)
KR (1) KR102210575B1 (lt)
CN (1) CN104994876A (lt)
AU (1) AU2013322854B2 (lt)
BR (1) BR112015006686B1 (lt)
CA (1) CA2885688C (lt)
CL (1) CL2015000744A1 (lt)
CY (1) CY1120939T1 (lt)
DK (1) DK2900269T3 (lt)
EA (1) EA032023B1 (lt)
ES (1) ES2687985T3 (lt)
HK (1) HK1214169A1 (lt)
HR (1) HRP20181462T1 (lt)
HU (1) HUE039878T2 (lt)
IL (1) IL237690B (lt)
LT (1) LT2900269T (lt)
MX (1) MX357035B (lt)
MY (1) MY183969A (lt)
NZ (1) NZ705860A (lt)
PH (1) PH12015500587A1 (lt)
PL (1) PL2900269T3 (lt)
PT (1) PT2900269T (lt)
RS (1) RS57875B1 (lt)
SG (2) SG10201702356VA (lt)
SI (1) SI2900269T1 (lt)
WO (1) WO2014048881A1 (lt)
ZA (1) ZA201502840B (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014030473A2 (pt) 2012-06-13 2017-06-27 Hoffmann La Roche novo diazaespirocicloalcano e azaespirocicloalcano
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JP6496730B2 (ja) 2013-11-26 2019-04-03 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規なオクタヒドロ−シクロブタ[1,2−c;3,4−c’]ジピロール−2−イル
MX370659B (es) 2014-03-26 2019-12-19 Hoffmann La Roche Compuestos bicíclicos como inhibidores de producción de autotaxina (atx) y ácido lisofosfatídico (lpa).
MX373236B (es) 2014-03-26 2020-05-08 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de producción de la autotaxina (atx) y ácido lisofosfatidico (lpa).
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
PE20180461A1 (es) 2015-09-24 2018-03-06 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de la atx
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
CA2984585A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
RS62574B1 (sr) * 2016-06-28 2021-12-31 Asamedic As Dvokomponentna kompozicija koja sadrži acetilsalicilnu kiselinu
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
AU2018276273B2 (en) * 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620834B1 (en) * 1999-07-02 2003-09-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
EP1948144A2 (en) * 2005-11-10 2008-07-30 Bayer HealthCare AG Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
IL237690A0 (en) 2015-05-31
EP2900269A1 (en) 2015-08-05
MX2015003728A (es) 2015-09-23
ZA201502840B (en) 2017-11-29
RS57875B1 (sr) 2018-12-31
EP2900269B1 (en) 2018-08-01
EA201500365A1 (ru) 2015-08-31
JP2015529234A (ja) 2015-10-05
PL2900269T3 (pl) 2019-02-28
EA032023B1 (ru) 2019-03-29
CA2885688C (en) 2021-03-02
SI2900269T1 (sl) 2018-10-30
SG11201501963RA (en) 2015-04-29
KR20150060869A (ko) 2015-06-03
PH12015500587A1 (en) 2015-05-11
JP6294888B2 (ja) 2018-03-14
AU2013322854A1 (en) 2015-04-02
KR102210575B1 (ko) 2021-02-02
HUE039878T2 (hu) 2019-02-28
MY183969A (en) 2021-03-17
WO2014048881A1 (en) 2014-04-03
NZ705860A (en) 2018-07-27
HRP20181462T1 (hr) 2018-11-02
BR112015006686A2 (pt) 2019-08-27
CN104994876A (zh) 2015-10-21
HK1214169A1 (zh) 2016-07-22
SG10201702356VA (en) 2017-04-27
BR112015006686B1 (pt) 2022-04-05
MX357035B (es) 2018-06-25
CY1120939T1 (el) 2019-12-11
ES2687985T3 (es) 2018-10-30
PT2900269T (pt) 2018-10-22
AU2013322854B2 (en) 2018-07-19
US10898500B2 (en) 2021-01-26
US20150202214A1 (en) 2015-07-23
CA2885688A1 (en) 2014-04-03
IL237690B (en) 2019-07-31
DK2900269T3 (en) 2018-10-01
CL2015000744A1 (es) 2016-01-08

Similar Documents

Publication Publication Date Title
PL2900269T3 (pl) Połączenie regorafenibu i kwasu acetylosalicylowego do leczenia raka jelita grubego
IL288181A (en) Cancer treatment methods
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2925888T3 (pl) Kompozycje i sposoby do stosowania w leczeniu nowotworów
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
ZA201406708B (en) Treatment of cancer with tor kinase inhibitors
IL234641A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors